• No results found

Microscopical evaluation of prognostic factors in colorectal cancer Mesker, W.E.

N/A
N/A
Protected

Academic year: 2021

Share "Microscopical evaluation of prognostic factors in colorectal cancer Mesker, W.E."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Microscopical evaluation of prognostic factors in colorectal cancer

Mesker, W.E.

Citation

Mesker, W. E. (2008, June 12). Microscopical evaluation of prognostic factors in colorectal cancer. Retrieved from https://hdl.handle.net/1887/12950

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/12950

Note: To cite this publication please use the final published version (if

applicable).

(2)

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,

volgens besluit van het College voor Promoties te verdedigen op donderdag 12 juni 2008

klokke 16.15 uur

door

Wilhelmina Engelina Mesker

geboren te Leiden in 1963

Microscopical evaluation of prognostic factors

in colorectal cancer

(3)

Promotiecommissie

Promotores: Prof. Dr. H.J. Tanke

Prof. Dr. R.A.E.M. Tollenaar Co-promotor: Dr. K. Szuhai

Referent: Prof. Dr. J.H.J.M. van Krieken, UMC St Radboud, Nijmegen Overige leden: Prof. Dr. C.J.H. van de Velde

Cover: Nick en Isabelle Heemskerk, 2008

Printed by Pasmans Offsetdrukkerij BV, Den Haag

The work presented in this thesis was supported in part by the European Community’s Sixth Framework program (DISMAL project, LSHC-CT-2005- 018911), Applied Imaging a Genetix Company, Zon-MW 945-05-021, the “Anna en Maurits de Kock Foundation”, the Dutch Cancer Society (Grant 2000-2211) and the European Community’s Sixth Framework program (Tumor-Host Genomics-1276640).

Financial support for publication of this thesis was kindly provided by:

Leica Microsystems B.V, Covidien Nederland B.V., Merck Serono.

With special thanks for their generous support to Applied Imaging a Genetix Company.

(4)

I have sent you my invitation,

the note inscribed on the palm of my hand by the fire of living.

Don't jump up and shout, "Yes, this is what I want! Let's do it!"

Just stand up quietly and dance with me.

- Oriah Mountain Dreamer, The Dance -

Lieve Pa, voor jou

(5)
(6)

Table of contents

Chapter 1 General Introduction 7

Chapter 2 Detection of tumor cells in bone marrow, peripheral blood and lymph 23 nodes by automated imaging devices.

Cell Oncol 2006; 28(4):141-150.

Chapter 3 Automated analysis of multiple sections for the detection of occult 35 cells in lymph nodes

Clin Cancer Res 2003; 9(13):4826-4834.

Chapter 4 Differences in genomic profiles of colorectal tumors of patients with 47 and without disseminated tumor cells in the bone marrow.

Chapter 5 The carcinoma–stromal ratio of colon carcinoma is an independent 65 factor for survival compared to lymph node status and tumor stage.

Cell Oncol. 2007; 29(5):387-98.

Chapter 6 Presence of a high amount of stroma and downregulation of SMAD4 79 predict for worse survival for stage I-II colon cancer patients.

Submitted.

Chapter 7 Summary and General Discussion 95

Chapter 8 Nederlandse samenvatting 107

Curriculum Vitae 115

List of publications 117

Figures chapters 3, 4 and 6 (color) 121

(7)

Referenties

GERELATEERDE DOCUMENTEN

Since the frequency of these cells in bone marrow and blood is sometimes as low as 1 per million and due to the fact that for the analysis of lymph nodes many sectioning levels have

In this study, we have compared visual examination of CK-immunostained serial sections (as gold standard) with au- tomated analysis and with the RT-PCR data from the referred

Using these three aberrations 10 out of 17 (59%) BM-positive patients could be identified as high-risk for the presence of disseminated tumor cells in the BM compared to 2 out of

Methods: In a retrospective study of 63 patients with colon cancer (stage I–III, 1990–2001) the carcinoma-percentage of the primary tumor was estimated on routine H&E

We have analyzed 135 stage I-II colon cancer patients with at least 11 years of follow-up for the proportion of tumor related stroma and for TGF-B-R2, SMAD4 and B-catenin.. It

Biological parameters such as the presence of micrometastases in lymph nodes, dissem- inated cells in bone marrow and circulating tumor cells in peripheral blood have shown to be

In hoofdstuk 3 wordt automatische microscopie toegepast voor het vinden van micrometastasen in de lymfeklieren van stadium II patiënten om patiënten te identificeren met een

Oosterwijk JC, Mesker WE, Ouwerkerk-van Velzen MC, Knepfle CF, Wiesmeijer KC, van den Burg MJ, Beverstock GC, Bernini LF, Van Ommen GJ, Kanhai HH, Tanke HJ: Development of